OR HB2292

Requires health insurers to cover FDA-approved drugs for HIV prevention (PrEP) and treatment, along with related services such as office visits, testing, vaccinations, and monitoring, without cost-sharing, coinsurance, or deductibles for prevention drugs and services.

Prohibits insurers from requiring prior authorization for preexposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and HIV/AIDS treatment drugs.

Prohibits the Oregon Health Authority and coordinated care organizations from requiring prior authorization or step therapy for FDA-approved HIV prevention or treatment drugs prescribed to Medicaid recipients when deemed medically necessary.

Increases expenditure limits for the Public Employees' Benefit Board by $767,644 and the Oregon Educators Benefit Board by $682,867 for the biennium beginning July 1, 2025, to cover implementation costs.

Applies to health benefit plans offered, renewed, or extended on or after the effective date of the Act.